Ottawa, Canada, August 7, 2019 – Evidence Partners, providers of the world’s only commercially available software solution for producing regulatory compliant systematic literature reviews, a cornerstone of evidence-based research, is undertaking an aggressive growth strategy for its Ottawa-based workforce.

“This is an exciting time for our team,” said Peter O’Blenis, CEO of Evidence Partners. “Demand for our products continues to accelerate, as the global healthcare industry looks to keep up with the increasing requirement for evidence generation.”

The company is currently in hiring mode, with plans to grow its headcount by 30% before year-end. Opportunities are available across the organization to accelerate the development and promotion of cutting-edge software tools that leverage artificial intelligence to make it faster and easier to produce high-quality evidence. The expansion comes just a year after Evidence Partners moved into new office space in Kanata North, and has led the company to lease additional space adjacent to its current site.

Used to guide healthcare policy and meet regulatory requirements for medical device and pharmaceutical manufacturers, evidence-based research depends largely on the systematic review of existing literature on a given topic or product. In the EU, the medical device industry is facing a dramatic increase in the requirement for systematic literature review, brought on by new regulations that come into effect in May 2021.

“There are simply not enough people qualified to handle the workload as a result of the new EU medical device requirements,” said O’Blenis. “The industry is looking for practical ways to create research capacity. Our solutions are playing a big role in enabling organizations to keep up with the increasing demands on their research talent.”

Evidence Partners Inc., provider of the world’s first AI-enabled literature review automation software, DistillerSR, today announced that it has been selected by the Lazaridis Institute to be part of the sixth cohort of the Lazaridis ScaleUp Program. The prestigious program helps Canada’s highest potential companies accelerate their growth and enhance their ability to compete internationally through mentorship, intensive workshops, and access to a global network of experts. Evidence Partners was one of 13 firms selected for the program.

“We are honoured to be selected into this highly respected program and to be recognized as one of the 13 most promising scaleup companies in Canada,” said Peter O’Blenis, CEO, Evidence Partners. “The timing of our selection is ideal. We are growing quickly, expanding market share globally, and investing aggressively in our product, AI-technologies, and, of course, our Ottawa-based team. This program will help to both focus and accelerate these efforts.”

Systematic literature reviews are the cornerstone of evidence-based research. Medical and scientific researchers use systematic literature reviews to collect secondary data, critically appraise research studies, and synthesize findings qualitatively or quantitatively.  The challenge with systematic reviews is that they are difficult to do, take a long time, and are error-prone.

DistillerSR is used by universities, governments and non-governmental organizations, pharmaceutical and medical device companies, as well as contract research organizations. The cloud-based platform brings together AI and intelligent workflows that automate the management of researchers’ systematic collection of secondary data to produce transparent, audit-ready and compliant literature reviews faster and more cost-effectively. As a result, DistillerSR enables researchers to inform time-sensitive critical health policies, clinical practice guidelines, and regulatory submissions.


About Evidence Partners
For more information about Evidence Partners and DistillerSR, visit

Media Contact
Chris Wright
[email protected]